1 in infants exposed to fluoxetine in the third trimester compared with those exposed in early pregnancy. Spencer 2 reported a term infant who had prominent neurobehavioral symptoms and respiratory distress, with the resolution of symptoms within 96 hours. Hematologic and neurologic side effects were described in another term neonate by Mhanna et al., 3 with the resolution of symptoms in 2 weeks. The present report describes marked motor automatism resembling seizures, exaggerated neurobehavioral symptoms, and skin manifestations in a preterm infant exposed to fluoxetine hydrochloride in utero.
CASE REPORT
A 3270-gm infant boy was delivered by normal spontaneous vaginal delivery at 35 weeks' gestation to a 28-year-old gravida 2, para 2 mother. She had regular prenatal care with past history significant for major depression and was on fluoxetine hydrochloride once daily. The medication was temporarily discontinued in the first trimester but was restarted at 40 mg every day for the relapse of depression and continued regularly throughout pregnancy. The mother had noticed fluttering movements of the fetus distinct from the regular movements during the last 2 months of pregnancy. At birth, the infant had Apgar scores of 4, 7, and 9 at 1, 5, and 10 minutes, respectively. At 4 hours of age, the baby was tachypneic, with respiratory rate of 100/minute, and was in respiratory distress with grunting, flaring, and retractions. Sepsis workup was done and antibiotics were started. Tachypnea resolved within 24 hours, but the infant was observed to be increasingly jittery over the next few hours. By 36 hours, the infant was tremulous, agitated, and had three to four episodes of seizure-like activity. The movements were characterized by twitching of face and eyebrows, grimacing, roving movements of eyes, and flailing movements of upper and lower extremities. Each episode lasted from 20 seconds to 1 minute and could not be abated by voluntarily holding of the limbs. The infant was then transferred from the regular newborn nursery to a tertiary care neonatal intensive care unit at 48 hours of age. Physical examination was remarkable for an erythematous rash on both cheeks; petechiae on the abdomen, chest, and extremities; and scleral icterus. He had increased tone, his head was extended in an opisthotonic posture, and had exaggerated reflexes. The infant's white blood cell count was 13,000, with 50 neutrophil and no band forms; the hematocrit was 54.2 mg/dl, and platelets were 350,000. Electrolytes, glucose, calcium, blood-urea-nitrogen, creatinine, and serum ammonia were normal. Urine toxicological screen was negative for recreational drugs. A cerebrospinal fluid examination was normal. Serum bilirubin levels were within normal limits.
An electroencephalogram failed to reveal any evidence of underlying epileptic activity; B6 injection did not modify the movements or electrical activity. Head ultrasound was normal. Blood and cerebrospinal fluid cultures were negative, including a viral culture for herpes. Skin manifestations resolved between 48 and 72 hours, but seizure-like activity peaked, with five to eight episodes per day. By 144 hours, jitteriness and tremulousness decreased and feedings were started. There was resolution of symptoms over the next 48 hours; feedings were advanced, and the infant was discharged from the hospital at 172 hours of age. Fluoxetine and norfluoxetine levels drawn at 96 hours of age were 92 and 34 ng/ml, respectively. Follow-up fluoxetine levels were not obtained (typical range is 50 to 480 ng/ml and 50 to 450 ng/ml for fluoxetine and norfluoxetine, respectively). A neurodevelopmental examination done at 4 months of age was within normal limits.
We describe a preterm infant with marked motor automatism and skin manifestations after being exposed to fluoxetine in utero. The fluoxetine level drawn at 96 hours of age was 92 ng / ml, which was in adult therapeutic range. The neurologic symptoms resolved by 7 days and follow -up at 4 months revealed normal neurodevelopmental examination. 
DISCUSSION
This is the first case report of fluoxetine toxicity in a preterm infant with a markedly exaggerated motor automatism as the presenting symptom. These movements probably had their onset in utero, as evidenced by maternal history of fluttering movements in the third trimester that were distinct from regular fetal movements. The fluoxetine level drawn at 96 hours of age was 92 ng/ml, which was within the adult therapeutic range (typical range is 50 to 480 ng/ ml). The long half-life of fluoxetine (4 to 6 days) results in slower elimination. 3 The other neurobehavioral symptoms of this infant were similar to those described in previous reports on term infants. 2, 3 Fluoxetine, the parent compound, may be responsible for the central nervous system side effects as described in reports of toxicity in adults; these side effects include nervousness, tremors, jitteriness, and occasionally seizures. Bruising and bleeding disorders with increased hematoma frequency at birth also have been described with fluoxetine exposure in utero. 4 Serotonininduced alterations in vascular tone and platelet dysfunction 3 ± 5 may be responsible for the petechiae and erythematous rash noted in this infant.
Chambers et al., 1 have reported poor neonatal adaptation, including jitteriness, cyanosis on feeding, and respiratory difficulties, in 31.5% of infants exposed to fluoxetine in the third trimester compared with 8.9% infants exposed to fluoxetine in the first trimester. The details of onset, duration, and resolution of symptoms in these infants were not described. Goldstein 6 prospectively identified 112 pregnancies in which the mother was exposed to fluoxetine in the third trimester and evaluated postnatal complications using telephone interview by reporters. He reported no consistent, recurring, or dose-related effects in the newborns other than jitteriness, irritability, and hyperbilirubinemia in 15 of 115 infants. The validity of the data collection method used in this study is of concern, because incomplete reporting can be expected, as acknowledged by the author. The plasma concentrations of fluoxetine were not measured in the 15 infants exhibiting milder neurobehavioral effects, despite the fact that these infants were identified prospectively during pregnancy.
Although no life-threatening complications have been noted in infants exposed to maternal fluoxetine, the present report suggests that marked motor automatism, including seizure-like activity, can be expected in preterm infants. Because fluoxetine is metabolized primarily in the liver, the prematurity of the infant and the immaturity of the liver may account for the multisystem involvement and the protracted course. A definitive evaluation of the neurobehavioral effects is warranted using case-controlled studies, especially for those infants exposed in the third trimester.
